Round One Goes To Indian Cos As Roche Loses Patent Fight On Valcyte
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In a judgment that seasoned intellectual property experts predict will impact the course of Indian jurisprudence, the Indian Patent Office has rejected the patent claims of Swiss drug maker Roche over the antiviral drug Valcyte (valgancyclovir) mainly on grounds of lack of inventiveness